Healthcare provider profile · identity verified

Joseph K Daprano, MD

Internal Medicine · CLEVELAND, OH · NPI 1881630283

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	647	192
Amlodipine Besylate	Amlodipine Besylate	560	163
Lisinopril	Lisinopril	315	88
Albuterol Sulfate Hfa	Albuterol Sulfate	298	97
Omeprazole	Omeprazole	266	69
Metformin Hcl	Metformin Hcl	227	58
Hydrochlorothiazide	Hydrochlorothiazide	197	57
Losartan Potassium	Losartan Potassium	160	41
Metoprolol Succinate	Metoprolol Succinate	159	46
Fluticasone Propionate	Fluticasone Propionate	150	57
Gabapentin	Gabapentin	111	37
Spironolactone	Spironolactone	108	25
Tamsulosin Hcl	Tamsulosin Hcl	99	34
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	99	30
Pravastatin Sodium	Pravastatin Sodium	97	32
Metoprolol Tartrate	Metoprolol Tartrate	93	24
Naproxen	Naproxen	84	21
Carvedilol	Carvedilol	83	25
Furosemide	Furosemide	79	20
Tramadol Hcl	Tramadol Hcl	78	suppressed
Famotidine	Famotidine	73	18
Ibuprofen	Ibuprofen	73	25
Simvastatin	Simvastatin	72	21
Glipizide Er	Glipizide	70	24
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	68	18
Diclofenac Sodium	Diclofenac Sodium	67	30
Meloxicam	Meloxicam	67	17
Isosorbide Mononitrate Er	Isosorbide Mononitrate	64	15
Levothyroxine Sodium	Levothyroxine Sodium	64	21
Atenolol	Atenolol	62	17
Latanoprost	Latanoprost	60	17
Eliquis	Apixaban	57	12
Januvia	Sitagliptin Phosphate	57	13
Sertraline Hcl	Sertraline Hcl	56	18
Rosuvastatin Calcium	Rosuvastatin Calcium	55	13
Trazodone Hcl	Trazodone Hcl	55	13
Hydrocortisone	Hydrocortisone	53	21
Esomeprazole Magnesium	Esomeprazole Magnesium	52	11
Potassium Chloride	Potassium Chloride	51	19
Spiriva Handihaler	Tiotropium Bromide	43	12
Montelukast Sodium	Montelukast Sodium	42	suppressed
Allopurinol	Allopurinol	41	14
Clonidine Hcl	Clonidine Hcl	40	14
Farxiga	Dapagliflozin Propanediol	38	suppressed
Prednisone	Prednisone	36	17
Amitriptyline Hcl	Amitriptyline Hcl	35	suppressed
Hydralazine Hcl	Hydralazine Hcl	33	suppressed
Pregabalin	Pregabalin	33	suppressed
Symbicort	Budesonide/Formoterol Fumarate	33	11
Ammonium Lactate	Ammonium Lactate	32	11
Trulicity	Dulaglutide	31	suppressed
Xarelto	Rivaroxaban	29	11
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	28	suppressed
Incruse Ellipta	Umeclidinium Bromide	28	suppressed
Alendronate Sodium	Alendronate Sodium	27	suppressed
Cilostazol	Cilostazol	27	suppressed
Finasteride	Finasteride	27	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	27	suppressed
Chlorthalidone	Chlorthalidone	25	suppressed
Glimepiride	Glimepiride	25	suppressed
Topiramate	Topiramate	25	suppressed
Valsartan	Valsartan	25	suppressed
Azelastine Hcl	Azelastine Hcl	24	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	24	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	24	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	24	suppressed
Clopidogrel	Clopidogrel Bisulfate	23	12
Enalapril Maleate	Enalapril Maleate	21	suppressed
Ezetimibe	Ezetimibe	21	suppressed
Meclizine Hcl	Meclizine Hcl	21	suppressed
Propranolol Hcl	Propranolol Hcl	21	suppressed
Glipizide	Glipizide	20	suppressed
Jardiance	Empagliflozin	20	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	20	suppressed
Valacyclovir	Valacyclovir Hcl	20	suppressed
Nifedipine Er	Nifedipine	19	suppressed
Peg-3350 And Electrolytes	Peg3350/Sod Sulf,bicarb,cl/Kcl	19	17
Verapamil Er	Verapamil Hcl	19	suppressed
Breo Ellipta	Fluticasone/Vilanterol	18	suppressed
Dorzolamide Hcl	Dorzolamide Hcl	18	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	18	suppressed
Lovastatin	Lovastatin	18	suppressed
Novolin 70-30 Flexpen	Insulin Nph Hum/Reg Insulin Hm	18	suppressed
Paroxetine Hcl	Paroxetine Hcl	18	suppressed
Qvar Redihaler	Beclomethasone Dipropionate	18	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	17	suppressed
Metformin Hcl Er	Metformin Hcl	17	suppressed
Nystatin	Nystatin	17	suppressed
Entresto	Sacubitril/Valsartan	16	suppressed
Gavilyte-G	Peg3350/Sod Sulf,bicarb,cl/Kcl	16	16
Ventolin Hfa	Albuterol Sulfate	16	suppressed
Bumetanide	Bumetanide	15	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	15	suppressed
Lactulose	Lactulose	15	suppressed
Linzess	Linaclotide	15	suppressed
Myrbetriq	Mirabegron	15	suppressed
Solifenacin Succinate	Solifenacin Succinate	15	suppressed
Tizanidine Hcl	Tizanidine Hcl	15	suppressed
Tradjenta	Linagliptin	15	suppressed
Bupropion Xl	Bupropion Hcl	14	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	14	suppressed
Nitroglycerin	Nitroglycerin	14	suppressed
Acyclovir	Acyclovir	13	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	13	suppressed
Baclofen	Baclofen	13	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	13	suppressed
Spiriva Respimat	Tiotropium Bromide	13	suppressed
Varenicline Tartrate	Varenicline Tartrate	13	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	12	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	12	suppressed
Flunisolide	Flunisolide	11	suppressed
Ketoconazole	Ketoconazole	11	suppressed
Klor-Con M20	Potassium Chloride	11	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Methocarbamol	Methocarbamol	11	suppressed
Novolin 70-30	Insulin Nph Hum/Reg Insulin Hm	11	suppressed
Ozempic	Semaglutide	11	suppressed
Timolol Maleate	Timolol Maleate	11	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error